RecruitingNCT05224778
DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Assessing Pediatric Endpoints in DM1 (ASPIRE-DM1)
Sponsor
Virginia Commonwealth University
Enrollment
50 participants
Start Date
Aug 24, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
Eligibility
Max Age: 59 Months
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with cdm and congenital myotonic dystrophy. The study is currently recruiting participants at 5 locations. People eligible for this study include up to age 59 Months.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05224778
Related Trials
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
NCT067478841 location
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
NCT000821081 location
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
NCT0500412914 locations
Myotonic Dystrophy Family Registry
NCT023987861 location